The global leaderboard of wealth: $1.2 Quadrillion of Assets ranked by Market Cap
In-depth research + analysis available with Pro ($3.99/mo) or Pro Plus ($9.99/mo). Everything else on this page is free.
Article
Article
Article
Article
Absci Corporation (ABSI) is making waves in the biopharmaceutical sector by leveraging artificial intelligence to accelerate drug discovery. As it progresses through human trials with its lead program, ABS-201, investor interest is surging. This article explores the company's potential, the implications of its AI-driven approach, and the broader market context. ## BODY: ### Introduction: The Intersection of AI and Biopharmaceuticals In recent years, the biopharmaceutical industry has witnesse